Lowest Price Guaranteed From USD 4,799
The pharmaceutical fill finish manufacturing market is estimated to be worth $1.6 billion in 2021 and is expected to grow at CAGR of 6% during the forecast period. Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA’s Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulatory review in the same year. Given that the demand for small molecule drugs is still on the rise, the importance of contract manufacturing and third party services is also increasing in the pharmaceutical industry. Sterile fill / finish is considered among the most crucial steps in the pharmaceutical production process. In fact, aseptic conditions during fill / finish operations are not only essential for ensuring end user safety, but also maintaining pharmacological efficacy and product quality. As small molecule APIs are gradually becoming more complex, the demand for appropriate aseptic fill / finish processes is growing.
Given the high cost of specialized equipment and the affiliated expertise required for aseptic fill / finish operations, it is difficult for drug developer companies with limited finances and capacity constraints to meet clinical / commercial scale demands. This has led many of the smaller players in the industry and certain pharma giants, as well, to outsource various aspects of their production processes, including fill / finish, to contract service providers. Currently, over 130 companies are actively providing sterile fill / finish services for small molecules. In the recent past, many of the aforementioned service providers have also forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings. We believe that this trend is likely to persist in the foreseen future, as well. Overall, the contract services market for pharmaceutical fill finish manufacturing is anticipated to witness steady market growth during the forecast period.
Examples of key companies engaged in pharmaceutical fill finish manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Albany Molecular Research (AMRI), Pii (Pharmaceutics International), Ajinomoto Bio-Pharma Services, Catalent Pharma Solutions, Pfizer CentreOne, Delpharm, Rompharm, CordenPharma, Mithra CDMO, Pierre Fabre, APL, Square Pharmaceuticals and Wockhardt. This market report includes an easily searchable excel database of all the companies providing small molecule aseptic fill finish manufacturing services, worldwide.
Several recent developments have taken place in the field of pharmaceutical fill finish manufacturing market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Pharmaceutical Fill Finish Manufacturing Market, 2020-2030’ market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the pharmaceutical fill finish manufacturing market. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in pharmaceutical fill finish manufacturing market.In addition to other elements, the market research report includes:
The key objective of pharmaceutical fill finish manufacturing market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for pharmaceutical fill finish manufacturing market during the forecast period. Based on parameters, such as such as growth of the overall pharmaceutical market, the cost associated with fill / finish operation and outsourcing trends related to these operations, we have provided an informed estimate on the likely evolution of the market over the forecast period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of
[A] fill / finish technique (aseptic filling, terminal sterilization and blow-fill-seal)
[B] type of packaging (ampoules, bottles, pre-filled syringes and vials)
[C] type of dosage form (liquid, lyophilized and others)
[D] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia-Pacific (Australia, India, South Korea and rest of the Asia), Middle East and North Africa and Latin America).
To account for the uncertainties associated with this industry and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.